Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lexaria Bioscience (LEXX) Equity Average (2016 - 2025)

Historic Equity Average for Lexaria Bioscience (LEXX) over the last 13 years, with Q4 2025 value amounting to $4.0 million.

  • Lexaria Bioscience's Equity Average fell 5365.89% to $4.0 million in Q4 2025 from the same period last year, while for Nov 2025 it was $4.0 million, marking a year-over-year decrease of 5365.89%. This contributed to the annual value of $5.3 million for FY2025, which is 299.46% up from last year.
  • Per Lexaria Bioscience's latest filing, its Equity Average stood at $4.0 million for Q4 2025, which was down 5365.89% from $4.3 million recorded in Q3 2025.
  • Lexaria Bioscience's Equity Average's 5-year high stood at $12.3 million during Q4 2021, with a 5-year trough of $3.2 million in Q4 2023.
  • In the last 5 years, Lexaria Bioscience's Equity Average had a median value of $7.4 million in 2022 and averaged $7.4 million.
  • As far as peak fluctuations go, Lexaria Bioscience's Equity Average surged by 47008.04% in 2021, and later tumbled by 5444.99% in 2023.
  • Quarter analysis of 5 years shows Lexaria Bioscience's Equity Average stood at $12.3 million in 2021, then crashed by 43.56% to $6.9 million in 2022, then crashed by 54.45% to $3.2 million in 2023, then skyrocketed by 170.39% to $8.5 million in 2024, then crashed by 53.66% to $4.0 million in 2025.
  • Its last three reported values are $4.0 million in Q4 2025, $4.3 million for Q3 2025, and $6.3 million during Q2 2025.